צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Amicus Corp (FOLD)

Amicus Therapeutics specializes in the therapy of rare genetic pathologies, relying on regulatory approvals and patent protection. Financial success is based on the commercialization of Galafold and the implementation of Pombiliti. The narrow niche of metabolic disorders is offset by the high margins of unique products. The current year-over-year (TTM) revenue growth rate visualizes the business cycle phase, while the 20.10 indicator reflects the status of sales dynamics.
amicusrx.com (FOLD) - פילוחי מדדים ודוחות פיננסיים

The monopoly position of Amicus Therapeutics (FOLD) in the orphan drug segment directly determines the dynamics of the rolling annual sales growth rate. This metric measures real market demand, stripping short-term volatility from the business's fundamental basis. The calculation is based on a continuous comparison of current TTM revenue against the same period last year. Stable growth confirms the company's exceptional pricing power and capital resilience.